Hadie Adams1,2, Hieab H H Adams3, Christina Jackson1, Jordina Rincon-Torroella1, George I Jallo1, Alfredo Quiñones-Hinojosa4. 1. Department of Neurosurgery and Oncology, Johns Hopkins School of Medicine, 1550 Orleans Street, Cancer Research Building II Room 253, Baltimore, MD, 21231, USA. 2. Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK. 3. Division of Neuro-Epidemiology, Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands. 4. Department of Neurosurgery and Oncology, Johns Hopkins School of Medicine, 1550 Orleans Street, Cancer Research Building II Room 253, Baltimore, MD, 21231, USA. aquinon2@jhmi.edu.
Abstract
PURPOSE: The benefit of radical resections for glioblastoma patients remains a source of contention in the literature. Few studies have been conducted in pediatric patients, and it is becoming increasingly evident that data regarding adult glioblastoma (GB) patients cannot be generalized to pediatric patients affected by this neoplasm. A comparative effectiveness study is performed for different extent of resection (EOR) groups in the largest cohort of pediatric GB (pGB) patients. METHODS: The Surveillance, Epidemiology, and End Results (SEER) cancer registry was used to identify pGB patients from 1988 through 2009. Multivariate- and multiple propensity score (mPS)-adjusted analyses were used to determine the effect of gross total resection (GTR), partial resection (PR), and biopsy (Bx) on overall survival. Survival prospects were summarized using direct adjusted survival curves. RESULTS: A total of 342 pGB patients were identified, and 35.4 % of patients received a GTR, 28.8 % PR, 17.3 % Bx, and 17.0 % did not undergo surgery. In our cohort, a median overall survival of 12 months was observed with 1-, 2-, and 5-year survival rates of 51.7, 28.3, and 15.7 %, respectively. EOR was a predictor of survival in both the multivariate- (P < 0.001) and mPS-adjusted model (P < 0.001). Compared to the GTR group, a higher mortality rate was observed in patients who underwent a PR (HR 1.50; 95 % CI, 1.02-2.21) or Bx (HR 1.87; 95 % CI, 1.18-2.98). There were no significant differences in (adjusted) mortality risk between the PR and Bx groups. CONCLUSION: Our study suggests that GTR is independently associated with improved survival for pediatric patients with glioblastoma.
PURPOSE: The benefit of radical resections for glioblastomapatients remains a source of contention in the literature. Few studies have been conducted in pediatric patients, and it is becoming increasingly evident that data regarding adult glioblastoma (GB) patients cannot be generalized to pediatric patients affected by this neoplasm. A comparative effectiveness study is performed for different extent of resection (EOR) groups in the largest cohort of pediatric GB (pGB) patients. METHODS: The Surveillance, Epidemiology, and End Results (SEER) cancer registry was used to identify pGBpatients from 1988 through 2009. Multivariate- and multiple propensity score (mPS)-adjusted analyses were used to determine the effect of gross total resection (GTR), partial resection (PR), and biopsy (Bx) on overall survival. Survival prospects were summarized using direct adjusted survival curves. RESULTS: A total of 342 pGBpatients were identified, and 35.4 % of patients received a GTR, 28.8 % PR, 17.3 % Bx, and 17.0 % did not undergo surgery. In our cohort, a median overall survival of 12 months was observed with 1-, 2-, and 5-year survival rates of 51.7, 28.3, and 15.7 %, respectively. EOR was a predictor of survival in both the multivariate- (P < 0.001) and mPS-adjusted model (P < 0.001). Compared to the GTR group, a higher mortality rate was observed in patients who underwent a PR (HR 1.50; 95 % CI, 1.02-2.21) or Bx (HR 1.87; 95 % CI, 1.18-2.98). There were no significant differences in (adjusted) mortality risk between the PR and Bx groups. CONCLUSION: Our study suggests that GTR is independently associated with improved survival for pediatric patients with glioblastoma.
Entities:
Keywords:
Extent of resection; GBM; Glioblastoma; Pediatric; Surgery; Survival
Authors: Stephanie M Perkins; Joshua B Rubin; Jeffrey R Leonard; Matthew D Smyth; Issam El Naqa; Jeff M Michalski; Joseph R Simpson; David L Limbrick; Tae S Park; David B Mansur Journal: Int J Radiat Oncol Biol Phys Date: 2011-01-08 Impact factor: 7.038
Authors: P Chastagner; C Kalifa; F Doz; E Bouffet; J C Gentet; M M Ruchoux; S Bracard; E Desandes; D Frappaz Journal: Pediatr Blood Cancer Date: 2007-11 Impact factor: 3.167
Authors: Maryam Fouladi; Daniel L Hunt; Ian F Pollack; Gregor Dueckers; Peter C Burger; Laurence E Becker; Allen J Yates; Floyd H Gilles; Richard L Davis; James M Boyett; Jonathan L Finlay Journal: Cancer Date: 2003-09-15 Impact factor: 6.860
Authors: J H Wisoff; J M Boyett; M S Berger; C Brant; H Li; A J Yates; P McGuire-Cullen; P A Turski; L N Sutton; J C Allen; R J Packer; J L Finlay Journal: J Neurosurg Date: 1998-07 Impact factor: 5.115
Authors: Alok Mohan Uppar; Harsha Sugur; A R Prabhuraj; M Bhaskara Rao; B Indira Devi; S Sampath; A Arivazhagan; Vani Santosh Journal: Childs Nerv Syst Date: 2019-05-31 Impact factor: 1.475
Authors: John T Lucas; David A Cooper; Scott Hwang; Christopher Tinkle; Xingyu Li; Yimei Li; Brent Orr; Thomas E Merchant; Alberto Broniscer Journal: Int J Radiat Oncol Biol Phys Date: 2017-05-04 Impact factor: 7.038
Authors: Aleksandra Napieralska; Aleksandra Krzywon; Agnieszka Mizia-Malarz; Joanna Sosna-Zielińska; Ewa Pawłowska; Małgorzata A Krawczyk; Katarzyna Konat-Bąska; Aneta Kaczorowska; Anna Dąbrowska; Maciej Harat Journal: Cancers (Basel) Date: 2021-04-24 Impact factor: 6.639
Authors: Meng Liu; Jigisha P Thakkar; Catherine R Garcia; Therese A Dolecek; Lars M Wagner; Emily Van Meter Dressler; John L Villano Journal: Cancer Med Date: 2018-03-13 Impact factor: 4.452